• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case series of dupilumab for vitiligo and alopecia areata in the setting of atopic dermatitis.

作者信息

Patel Dev, Hu Ben, Alani Omar, Silverberg Nanette

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

JAAD Case Rep. 2025 Jul 15;64:46-49. doi: 10.1016/j.jdcr.2025.05.048. eCollection 2025 Oct.

DOI:10.1016/j.jdcr.2025.05.048
PMID:40933636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12418822/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/664833a2c76f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/b1ade2b5f059/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/52fb51cec466/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/69d05503e738/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/664833a2c76f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/b1ade2b5f059/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/52fb51cec466/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/69d05503e738/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d295/12418822/664833a2c76f/gr4.jpg

相似文献

1
A case series of dupilumab for vitiligo and alopecia areata in the setting of atopic dermatitis.在特应性皮炎背景下，使用度普利尤单抗治疗白癜风和斑秃的病例系列。
JAAD Case Rep. 2025 Jul 15;64:46-49. doi: 10.1016/j.jdcr.2025.05.048. eCollection 2025 Oct.
2
[Hair growth with dupilumab in alopecia areata universalis and atopic dermatitis].[度普利尤单抗治疗泛发性斑秃和特应性皮炎时的毛发生长]
Dermatologie (Heidelb). 2022 Jul;73(7):556-559. doi: 10.1007/s00105-021-04898-y. Epub 2021 Oct 5.
3
Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis.白癜风和斑秃与特应性皮炎的相关性：系统评价和荟萃分析。
JAMA Dermatol. 2015 May;151(5):522-8. doi: 10.1001/jamadermatol.2014.3324.
4
Real World Side-Effects of Dupilumab: A Narrative Review.度普利尤单抗的真实世界副作用：一项叙述性综述。
Australas J Dermatol. 2025 Sep;66(6):e324-e334. doi: 10.1111/ajd.14557. Epub 2025 Jun 25.
5
Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report.度普利尤单抗治疗斑秃和特应性皮炎儿科患者的毛发再色素沉着和再生：一例报告
Ther Adv Chronic Dis. 2023 Aug 4;14:20406223231191049. doi: 10.1177/20406223231191049. eCollection 2023.
6
Long-Term Efficacy of Dupilumab in Alopecia Areata.斑秃患者使用度普利尤单抗的长期疗效。
Am J Case Rep. 2022 Jun 21;23:e936488. doi: 10.12659/AJCR.936488.
7
Dupilumab's Successful Journey in Pityriasis Lichenoides Chronica Followed by the Intriguing Reemergence of Vitiligo after Monobenzone Depigmentation: A Case Report.度普利尤单抗治疗慢性苔藓样糠疹的成功历程及单苯甲醚脱色后白癜风的有趣复发：一例报告
Case Rep Dermatol. 2025 May 15;17(1):231-239. doi: 10.1159/000545212. eCollection 2025 Jan-Dec.
8
Clinical Characteristics of Super Responders to Anti-IL-4Rα Biologic Therapy in Atopic Dermatitis.特应性皮炎中抗IL-4Rα生物疗法超级应答者的临床特征
Dermatol Ther (Heidelb). 2025 Aug 16. doi: 10.1007/s13555-025-01514-y.
9
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
10
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.特应性皮炎患者度普利尤单抗眼部不良反应：系统评价。
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):820-835. doi: 10.1111/jdv.17981. Epub 2022 Feb 17.

本文引用的文献

1
Vitiligo: From Pathogenesis to Treatment.白癜风：从发病机制到治疗
J Clin Med. 2024 Sep 3;13(17):5225. doi: 10.3390/jcm13175225.
2
A Mendelian randomization study on the causal effects of circulating cytokines on the risk of vitiligo.一项关于循环细胞因子对白癜风风险因果效应的孟德尔随机化研究。
Front Med (Lausanne). 2024 Apr 17;11:1375339. doi: 10.3389/fmed.2024.1375339. eCollection 2024.
3
Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.专家关于在儿童、青少年和青年患者中使用外用治疗药物治疗白癜风的建议。
JAMA Dermatol. 2024 Apr 1;160(4):453-461. doi: 10.1001/jamadermatol.2024.0021.
4
Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus.在开始使用度普利尤单抗治疗难治性瘙痒后，程序性细胞死亡-1受体抑制剂诱导的白癜风出现意外改善。
JAAD Case Rep. 2023 Sep 26;42:31-34. doi: 10.1016/j.jdcr.2023.09.006. eCollection 2023 Dec.
5
Vitiligo during dupilumab therapy.度普利尤单抗治疗期间的白癜风。
JAAD Case Rep. 2023 Apr 26;36:51-53. doi: 10.1016/j.jdcr.2023.03.025. eCollection 2023 Jun.
6
Prevalence of Vitiligo among Children and Adolescents in the United States.美国儿童和青少年白癜风患病率。
Dermatology. 2023;239(2):227-234. doi: 10.1159/000528180. Epub 2023 Jan 11.
7
Vitiligo and atopic dermatitis in young girls: may Koebner phenomenon play a role?年轻女孩中的白癜风与特应性皮炎：同形反应可能起作用吗？
An Bras Dermatol. 2023 Jan-Feb;98(1):125-127. doi: 10.1016/j.abd.2021.02.014. Epub 2022 Nov 12.
8
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗治疗 6 月龄至 5 岁以下未控制特应性皮炎儿童患者的随机、双盲、安慰剂对照 3 期临床试验。
Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2.
9
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults.美国皮肤病学会指南：了解成人特应性皮炎相关的合并症。
J Am Acad Dermatol. 2022 Jun;86(6):1335-1336.e18. doi: 10.1016/j.jaad.2022.01.009. Epub 2022 Jan 24.
10
Prevalence of Vitiligo Among Adults in the United States.美国成年人白癜风患病率。
JAMA Dermatol. 2022 Jan 1;158(1):43-50. doi: 10.1001/jamadermatol.2021.4724.